Views 303
Citations 0
Comment & Response
August 12/26, 2013

Why Physicians Favored Lipitor Over Simvastatin—Reply

Author Affiliations
  • 1Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco

Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Intern Med. 2013;173(15):1473. doi:10.1001/jamainternmed.2013.7701

In Reply Dr Keller correctly cites the Food and Drug Administration safety communication regarding the 80-mg dose of simvastatin as a factor that may have influenced the prescribing of that agent relative to Lipitor (atorvastatin calcium; Pfizer Inc). The June 8, 2011, safety communication was preceded by an earlier notice on March 19, 2010, regarding the possibility that 80-mg simvastatin was associated with an increased risk of muscle injury relative to other drugs in the statin class. However, in the years leading up to these safety communications during which less-expensive generic simvastatin products were available (ie, 2007-2009), Lipitor was not only the most commonly prescribed statin, surpassing generic simvastatin, but also the most commonly prescribed drug, surpassing all other prescription drugs.1

First Page Preview View Large
First page PDF preview
First page PDF preview